Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination with Nivolumab in Subjects with High-risk Ocular Melanoma
Study of Ipilimumab in Combination with Nivolumab in Subjects with High-risk Ocular Melanoma
Sponsor: Bristol-Myers Squibb and Suthee Rapisuwon MD
Enrolling: Male and Female Patients
IRB Number: AAAR9971
U.S. Govt. ID: NCT03528408
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is a phase II clinical trial that will study the combination of adjuvant nivolumab and ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma. This study is being done to see if the combination of the study drugs is safe and effective in preventing the return of their cancer. If you are eligible for this study, you will receive nivolumab every 2 weeks plus ipilimumab every 6 weeks.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Were you diagnosed with high-risk ocular melanoma? Yes No
Did you previously undergo treatment for your ocular melanoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162